Doctor Reviews Top 6 Peptides (Hype or Healing?)

Dr. Ashley Froese Evaluates the Most Popular Peptides in 2026

Dr. Ashley Froese, a physician who runs the YouTube channel "This Is Not Covered," reviews six of the most talked-about peptides in the wellness and biohacking space. With 177K views, this video is a practical scorecard for people trying to figure out which peptides have substance behind the hype and which are running mostly on enthusiasm. Froese brings a clinical perspective that neither dismisses peptides wholesale nor accepts every claim at face value.

The title asks "Hype or Healing?" and Froese delivers honest verdicts for each of the six peptides she covers. Some land firmly in the "healing" category based on available evidence. Others sit closer to "hype" because the claims have outpaced the research. Most fall somewhere in between, with genuine potential that has not yet been fully validated in human studies.

BPC-157: The Tissue Repair Peptide

Froese starts with BPC-157, arguably the most popular peptide in the therapy space. Her assessment is consistent with the broader clinical consensus: the animal data is extensive and impressive, the proposed mechanisms are biologically plausible, and the anecdotal clinical reports are largely positive. The limitation is the near-total absence of randomized controlled human trials.

She gives BPC-157 a favorable rating for tissue repair and gut healing, noting that it is the peptide she is most comfortable discussing with patients because the volume of preclinical evidence is substantial enough to inform clinical reasoning even without formal human trial results. She recommends it most confidently for gut issues (where the oral route delivers the peptide directly to the target tissue) and for soft tissue injuries in patients who have not responded adequately to conventional treatment.

TB-500 (Thymosin Beta-4): The Recovery Peptide

TB-500 is a synthetic version of thymosin beta-4, a naturally occurring peptide that promotes cell migration, angiogenesis, and tissue remodeling. Froese notes that thymosin beta-4 itself has a longer research history than TB-500, with studies in wound healing, cardiac repair, and corneal injury going back decades.

Her assessment is that TB-500 has solid mechanistic support and promising clinical observations but shares the same evidence gap as BPC-157: limited controlled human studies. She discusses the "Wolverine stack" (BPC-157 plus TB-500 used together) and notes that while the rationale for combining them is logical (complementary healing mechanisms), the combination has not been studied in controlled trials.

Froese rates TB-500 as potentially beneficial for recovery from injury and surgery, with the caveat that expectations should be calibrated to the evidence level. It is not a proven treatment. It is a reasonable option to discuss with a knowledgeable practitioner.

Ipamorelin: The Growth Hormone Secretagogue

Ipamorelin stimulates the pituitary gland to release growth hormone. Froese explains that it works by mimicking ghrelin, the hunger hormone, which also triggers growth hormone release. Unlike direct growth hormone injection, ipamorelin works through your body's own regulatory feedback, which theoretically provides a more physiological growth hormone pattern.

Her assessment here is more cautious. The growth hormone increases from ipamorelin are modest compared to direct GH injection. Whether those modest increases translate to meaningful clinical benefits (better sleep, improved body composition, faster recovery) is debatable. Froese has patients who report improved sleep and recovery on ipamorelin, but she cannot rule out placebo effects given the modest magnitude of the hormonal change.

She rates ipamorelin as lower priority compared to BPC-157 and TB-500, primarily because the evidence for clinically meaningful benefits at typical doses is weaker. For patients with confirmed growth hormone deficiency, she would recommend working with an endocrinologist for proper GH replacement rather than using secretagogues.

CJC-1295: The Extended Growth Hormone Releaser

CJC-1295, often used in combination with ipamorelin, extends the duration of growth hormone release. Froese explains that CJC-1295 with DAC (drug affinity complex) has a longer half-life, producing sustained growth hormone elevation over days rather than the short pulse that ipamorelin alone provides.

Her concerns with CJC-1295 are similar to ipamorelin but amplified. The longer-duration growth hormone elevation is less physiological and may carry more risk of side effects like water retention, joint pain, and blood sugar changes. She has seen more side effect reports with CJC-1295 than with ipamorelin alone in her practice.

Froese rates this as a peptide that has applications in specific clinical scenarios (legitimate growth hormone optimization under medical supervision) but is not something she broadly recommends for general wellness or anti-aging. The risk-to-benefit ratio is less favorable than for the tissue-healing peptides.

PT-141 (Bremelanotide): The Sexual Health Peptide

PT-141 is unique on this list because it has actually gone through the FDA approval process. It is available as Vyleesi, an FDA-approved treatment for hypoactive sexual desire disorder (HSDD) in premenopausal women. PT-141 works by activating melanocortin receptors in the brain, specifically MC4R, which are involved in sexual arousal and desire.

Froese gives PT-141 credit for being one of the few peptides with legitimate regulatory approval for a specific indication. The clinical trial data supports its efficacy for HSDD, though the effect size is modest and the side effect profile (nausea, flushing, headache) limits its tolerability for some patients.

She notes that PT-141 is also used off-label for men, though the evidence for male applications is thinner. The compounded version is used more broadly than the brand-name product because of cost differences. Froese rates it positively for the specific indication it is approved for, with caveats about tolerability.

KPV: The Anti-Inflammatory Peptide

KPV is a tripeptide (just three amino acids) derived from alpha-melanocyte stimulating hormone (alpha-MSH). It has anti-inflammatory properties that have been studied primarily in the context of inflammatory bowel disease. Froese notes that KPV research is earlier-stage than BPC-157 or TB-500, with fewer animal studies and virtually no human trials.

She rates KPV as having interesting potential but being too early in its research journey to recommend with confidence. For gut inflammation specifically, she would lean toward BPC-157 as a better-studied option. KPV might prove useful, but the evidence base is not yet there.

The Practical Takeaway

Froese's overall message is that peptides as a category are not uniformly hyped or uniformly healing. Each one needs to be evaluated on its own evidence. BPC-157 and TB-500 have the strongest preclinical support for tissue healing. Growth hormone secretagogues have more limited evidence for clinically meaningful effects. PT-141 has actual FDA approval for a specific condition. And newer entries like KPV need more research before they earn confident recommendations.

For anyone starting their peptide research, this video provides a useful triage framework. Start with the peptides that have the deepest evidence base (BPC-157, TB-500) and be progressively more skeptical as you move toward compounds with thinner research backing.

The Cost-Benefit Analysis for Each Peptide

Froese adds a practical cost dimension to her analysis that many clinical discussions omit. Peptide therapy is not covered by insurance in most cases, making out-of-pocket cost a real factor in treatment decisions. BPC-157 and TB-500 are relatively affordable as peptides go, typically costing $100 to $200 per month at standard doses from quality compounding pharmacies. Growth hormone secretagogues tend to be more expensive, particularly when using combinations like ipamorelin plus CJC-1295, which can run $300 to $500 per month.

When you combine the evidence strength with the cost, the value proposition becomes clearer. BPC-157 offers the best combination of evidence support and affordability. TB-500 is a reasonable second-line option at a similar price point. Growth hormone secretagogues cost more and have weaker evidence for clinically meaningful benefits in people with normal GH levels, making them a harder sell from a pure value perspective.

Froese suggests that patients who are budget-conscious start with BPC-157 for their specific condition, evaluate the response over one cycle, and only add or switch to other peptides if the initial response is insufficient. This sequential approach avoids the common mistake of starting multiple peptides simultaneously, which makes it impossible to determine which one is responsible for any observed effects and increases cost unnecessarily.

For patients who have the budget for combination protocols, she recommends the BPC-157 plus TB-500 combination for tissue healing applications and reserves growth hormone secretagogues for patients with confirmed suboptimal GH levels or specific indications where GH optimization is the primary goal.

The peptide space is evolving rapidly, and Froese acknowledges that her assessments today may need updating as new data emerges. She recommends that viewers revisit the evidence for any peptide they are interested in at least annually, since the research pipeline is producing new studies at an accelerating pace. A peptide that falls in the "hype" category today could move to "healing" with a well-designed human trial, and vice versa if safety concerns emerge. Staying current with the evidence is part of being a responsible participant in the peptide therapy space, whether you are a patient or a practitioner.

Froese's final recommendation is straightforward: if you are new to peptides, start with the compound that has the most evidence for your specific condition. For most people, that means BPC-157 for tissue healing and gut issues. Use it at a standard dose for a defined cycle with clear outcome measures. If it works, you have found your answer. If it does not, you have learned something valuable about your condition. Then and only then consider adding or switching to other peptides. This sequential, evidence-informed approach avoids the common trap of trying everything at once and having no idea what is working, what is not, and what might actually be making things worse. Simplicity is more than cost-effective. It is scientifically sound.